European Patent Organisation

Kaival Brands Provides Business Update in Letter to Shareholders

Retrieved on: 
Wednesday, February 14, 2024

Operating Expenses decreased to $13.2 million compared to $15.6 million, with the decrease driven primarily by disciplined cost management.

Key Points: 
  • Operating Expenses decreased to $13.2 million compared to $15.6 million, with the decrease driven primarily by disciplined cost management.
  • As of October 31, 2023, Kaival Brands had working capital of approximately $1.9 million and total cash of approximately $0.5 million.
  • Through it all, we remain committed to steadfast compliance with established FDA requirements for our products and business as we have since our inception.
  • Those ten products remain available for sale through Kaival Brands, subject to FDA’s enforcement discretion.

Kaival Brands Looks to Address Key Market Opportunities Following Acquisition of Extensive Vaporizer and Inhalation Patent Portfolio

Retrieved on: 
Friday, June 9, 2023

In the near term, Kaival Brands expects to seek third-party licensing opportunities in the cannabis, hemp/CBD, nicotine and nutraceutical markets, as a means of monetizing its new patents.

Key Points: 
  • In the near term, Kaival Brands expects to seek third-party licensing opportunities in the cannabis, hemp/CBD, nicotine and nutraceutical markets, as a means of monetizing its new patents.
  • Importantly, in certain key aspects, the equity consideration was structured in a forward-looking manner with valuations or exercise prices struck at premiums to the current market price of Kaival Brands’ common stock.
  • The portfolio also includes a proprietary mobile device software application that is used in conjunction with certain patents in the portfolio.
  • To learn more about the acquisition and for a broader transaction overview, please see our release from May 31, 2023 .

Kaival Brands Acquires Extensive Vaporizer and Inhalation Patent Portfolio to Diversify Product Offerings and Create New Revenue Opportunities

Retrieved on: 
Wednesday, May 31, 2023

The acquired assets will be housed in Kaival Labs, Inc., a wholly owned subsidiary of Kaival Brands which develops new branded and white-label products and services in the vaporizer and inhalation technology sectors.

Key Points: 
  • The acquired assets will be housed in Kaival Labs, Inc., a wholly owned subsidiary of Kaival Brands which develops new branded and white-label products and services in the vaporizer and inhalation technology sectors.
  • The portfolio also includes a proprietary mobile device software application that is used in conjunction with certain patents in the portfolio.
  • “This is a transformative asset acquisition for Kaival Brands,” stated Eric Mosser, President and Chief Operating Officer of Kaival Brands.
  • Ellenoff Grossman & Schole LLP acted as legal counsel to Kaival Brands and the Gunster law firm acted as legal counsel to GoFire.

Everything Blockchain Announces Transfer of Incorporation to Florida

Retrieved on: 
Thursday, May 25, 2023

The transfer of corporate governance to Florida reflects the resident status of the majority of EBI’s management team and board members, as well as significant cost savings in corporate administration, oversight costs and taxes.

Key Points: 
  • The transfer of corporate governance to Florida reflects the resident status of the majority of EBI’s management team and board members, as well as significant cost savings in corporate administration, oversight costs and taxes.
  • EBI will maintain its corporate headquarters in Jacksonville, along with two of its wholly owned subsidiaries, EBI International, Inc. and Everything Blockchain Technology Corp.
  • There have been no changes made to the Board of Directors, management, business or operations of EBI as a result of the transfer.
  • This news follows shortly after EBI announced significant product updates to EB Control , as well as the application’s availability on any browser .

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

Retrieved on: 
Thursday, April 6, 2023

CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage biotech company focusing on inflammatory conditions, today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No. 3132021, with claims focused on its proprietary strain of beneficial AOB, in the class of Nitrosomonas eutropha. The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.

Key Points: 
  • -  AOBiome's clinical candidate B244 has demonstrated clinical efficacy on multiple therapeutic indications including: Mild-to-Moderate Atopic Dermatitis and associated Moderate-to-Severe Pruritus, and mild-to-moderate Acne Vulgaris
    CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage biotech company focusing on inflammatory conditions, today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No.
  • The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.
  • This patent follows on other related issued composition of matter patents in Japan, Canada, India and Australia.
  • "Getting a composition of matter patent speaks to the unique aspects of this proprietary strain of AOB which has shown superior growth, stability and metabolic activity when compared to other strains.

Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker

Retrieved on: 
Thursday, August 25, 2022

15861319.0) related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs).

Key Points: 
  • 15861319.0) related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs).
  • We are extremely pleased to receive this notice from the European patent office, said Chris Min, M.D., Ph.D., Interim Chief Executive Officer and Chief Medical Officer at Longeveron.
  • This patent will bolster our robust intellectual property portfolio and support our goal of delivering effective cell therapies for a range of aging-related and life-threatening conditions.
  • The patent is titled Methods for Monitoring Efficacy of Allogeneic Mesenchymal Stem Cell Therapy in a Subject.

INEO Granted Patent Protecting the INEO Welcoming System's Technology in Europe

Retrieved on: 
Wednesday, August 3, 2022

INEO's patented technology combines a traditional Electronic Article Surveillance (EAS) system with a digital media display in one integrated device.

Key Points: 
  • INEO's patented technology combines a traditional Electronic Article Surveillance (EAS) system with a digital media display in one integrated device.
  • "Receiving this patent in Europe is a significant milestone for INEO as we continue to expand our reach into new global markets," said Greg Watkin, Chairman and President of INEO.
  • INEO filed its first patent on July 11, 2016, with the Canadian Intellectual Patent Office, resulting in INEO being granted Canadian patent 2,936,044, on January 15, 2018.
  • The European Patent Organization granted this most recent patent after a substantive examination of the patent application.

GranBio has a validated European patent for 2G ethanol production

Retrieved on: 
Thursday, June 2, 2022

ATLANTA, June 2, 2022 /PRNewswire-PRWeb/ -- GranBio, a Brazilian and United States industrial biotechnology company, secured the unopposed confirmation of European Patent No. EP 3259360, originally granted on August 25, 2021. The European patent has been successfully validated by GranBio in 31 countries for patent protection: Albania, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Europe leads the global race for clean energy, being a strategic market that is transitioning away from fossil-fuel feedstocks and towards renewable feedstocks. The 31 patents cover the production of cellulosic ethanol (or another fermentation product) in these countries.

Key Points: 
  • ATLANTA, June 2, 2022 /PRNewswire-PRWeb/ -- GranBio, a Brazilian and United States industrial biotechnology company, secured the unopposed confirmation of European Patent No.
  • The 31 patents cover the production of cellulosic ethanol (or another fermentation product) in these countries.
  • "We are committed to be a relevant enabler of NetZero value chains from biomass to advanced biofuels such as 2G ethanol and 2G SAF and biochemicals.
  • The technology developed by GranBio to produce 2G ethanol has already been implemented at its plant located in So Miguel dos Campos, Alagoasthe first in the Southern Hemisphere dedicated to cellulosic ethanol.

Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing

Retrieved on: 
Monday, September 6, 2021

COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.
  • The TBA made its decision after considering Forwards appeal against the decision of the Opposition Division and third-party submissions from several opponents.
  • The TBA will issue detailed reasons for the decision in written form in due course, and following receipt and review of these, Forward will announce future plans for the Company.
  • The denial of a petition for review would end the Opposition Proceeding in favor of the opponents.

Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations

Retrieved on: 
Thursday, July 29, 2021

The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.

Key Points: 
  • The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.
  • A Decision to Grant is the European Examiners confirmation that the European Patent Office has decided to grant Kane the patent and has set the grant date.
  • "These patents are important additions to the existing portfolio covering Kanes coactiv+ technology platform," saidGordon Guay, the company's Chief Scientific Officer.
  • Its multi-functional and gentle formulation makes it a perfect companion treatment to DispersinB Hydrogel, also part of the Kane Biotech antibiofilm wound care portfolio.